• Mashup Score: 0

    When I was a trainee, I thought: am I going to be a surgeon or am I going to go into internal medicine? At that stage, we had a doctor…

    Tweet Tweets with this article
    • In our recent interview, Jeanin van Hooft discusses how UEG @my_ueg brings together experts in the area and the future of gastrointestinal endoscopy research. Read now 👉 https://t.co/pJh4q9QL4k #UEGWeek #medicalinnovation

  • Mashup Score: 2
    UEG Week 2022 - 1 year(s) ago

    Results of the REACT-2 trial, presented by Vipul Jairath (London, ON, Canada) suggest that treating to a target of ulcer healing was no more effective than standard symptom-based management for patients with Crohn’s disease. In this cluster-randomised trial, eligible practices were randomly assigned to an enhanced care algorithm (incorporating early adalimumab and antimetabolite combination…

    Tweet Tweets with this article
    • News - coverage of some of the highlights among the research presented at #UEGWeek - https://t.co/QbMLDZO50e #gitwitter https://t.co/Cr8qj3Udj0

  • Mashup Score: 0

    VIENNA — In a Healio video exclusive, Waqqas Afif, MD, reports results from the phase 3 UNIFI study, in which Stelara safely demonstrated sustained symptomatic and corticosteroid-free remission in adults with ulcerative colitis. According to Afif, 65% of patients who responded to the induction dose of Stelara (ustekinumab, Janssen) were in remission after 44 weeks of maintenance therapy. At

    Tweet Tweets with this article
    • #ICYMI from #UEGWeek 2022: #Stelara safe, effective for the long-term treatment of moderate to severe #UC @my_ueg #GITwitter #MedTwitter https://t.co/2PvgZV56jh

  • Mashup Score: 1

    VIENNA — In a Healio video exclusive, Waqqas Afif, MD, reports results from the phase 3 UNIFI study, in which Stelara safely demonstrated sustained symptomatic and corticosteroid-free remission in adults with ulcerative colitis. According to Afif, 65% of patients who responded to the induction dose of Stelara (ustekinumab, Janssen) were in remission after 44 weeks of maintenance therapy. At

    Tweet Tweets with this article
    • In a Healio video exclusive, @waqqasafif reports results presented at #UEGWeek 2022 from the phase 3 #UNIFI study, in which #Stelara safely demonstrated sustained symptomatic and corticosteroid-free remission in adults with #ulcerativecolitis #UC @my_ueg https://t.co/2PvgZV56jh

  • Mashup Score: 4

    In a Healio video exclusive, Simon Travis, DPhil, FRCP, consultant gastroenterologist the University of Oxford, highlighted the unmet need to treat bowel urgency among patients with ulcerative colitis.In online, quantitative, cross-sectional surveys of patients with moderate to severe UC conducted in the United States and Europe, bowel urgency was the second-most frequently reported symptom and

    Tweet Tweets with this article
    • #ICYMI from #UEGWeek (@my_ueg) 2022: Bowel urgency ‘dominates burden, fear of incontinence’ in #UC #IBD #GITwitter #MedTwitter https://t.co/nxioiZgguX